This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

36/100

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Background and objectives Deposition of β-amyloid and phosphorylated-tau proteins are major neuropathological abnormality in brain of patients with Alzheimer disease. This study aimed to study the role of various serum protein biomarkers to aid in the diagnosis and progression of Alzheimer disease. Methods Blood samples were collected from 96 patients with Alzheimer disease, 75 patients with mild cognitive impairment, and 70 geriatric controls at baseline. The number of patients (Alzheimer disease and mild cognitive impairment) who progressed after 1 year was 12, while the number of non-progressors was 24. Serum levels of β-amyloid1-42 (Aβ1-42), Tau, and phosphorylated-Tau181 (pTau) were quantified using surface plasmon resonance and further validated by Western blot. Results Comparison of proteins between the three groups revealed significantly lower Aβ1-42, higher Tau and pTau protein expression in serum of patients with Alzheimer disease as compared to patients with mild cognitive impairment and controls. In patients who progressed after one year, the baseline concentration of Aβ1-42 protein was significantly higher than their follow-up levels. Tau and pTau levels also increased significantly over the years. In non-progressors, no significant difference was observed in Aβ1-42, Tau, and pTau concentration between the baseline and follow up. Interpretation and conclusions Aβ1-42, Tau, and pTau proteins can serve as potential blood-based biomarkers for the diagnosis and monitoring the progression of Alzheimer disease.

Key findings

Results Comparison of proteins between the three groups revealed significantly lower Aβ1-42, higher Tau and pTau protein expression in serum of patients with Alzheimer disease as compared to patients with mild cognitive impairment and controls.
In patients who progressed after one year, the baseline concentration of Aβ1-42 protein was significantly higher than their follow-up levels.
Tau and pTau levels also increased significantly over the years.
In non-progressors, no significant difference was observed in Aβ1-42, Tau, and pTau concentration between the baseline and follow up.

Why it matters

In this follow-up study, people with Alzheimer's disease had lower serum Aβ1-42 and higher Tau and pTau than those with mild cognitive impairment and controls, and those who progressed showed falling Aβ1-42 and rising Tau and pTau over one year. It does not test a treatment or cure, but it suggests these blood proteins may help track diagnosis and progression.

Study details

Participants96
Evidence strengthLow

How this study scored 36/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (The Indian Journal of Medical Research)
Journal's citation record	1 / 4	The Indian Journal of Medical Research: journal h-index 94 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	1 / 4	96 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 1 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.5 citations a year over 2 year(s) since 2026
Impact for its field and year	3 / 6	Cited 4.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	0 / 4	Last-listed author Sharmistha Dey: h-index 1 (OpenAlex, whole career)
Institution's track record	0 / 3	All India Institute of Medical Sciences: institution h-index 440 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41949144)
Free to read	2 / 2	Free to read
Total	36 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Pradhan, R., Kumari, S., Singh, A. K., Rao, A. R., Yadav, Y., Upadhyay, A. D., et al. (2026). Blood level of β-amyloid, Tau, and p-Tau in mild cognitive impairment and Alzheimer disease: A follow up study. The Indian Journal of Medical Research. https://doi.org/10.25259/ijmr_2164_2025

Vancouver

Pradhan R, Kumari S, Singh AK, Rao AR, Yadav Y, Upadhyay AD, et al. Blood level of β-amyloid, Tau, and p-Tau in mild cognitive impairment and Alzheimer disease: A follow up study. The Indian Journal of Medical Research. 2026. doi:10.25259/ijmr_2164_2025. PMID: 41949144.

BibTeX

@article{pradhan2026-41949144,
  author  = {Pradhan, Rashmita and Kumari, Sakshi and Singh, Abhinay Kumar and Rao, Abhijith R. and Yadav, Yudhishthir and Upadhyay, Ashish Datt and Mehta, Pramod Kumar and Dey, Aparajit B. and others},
  title   = {{Blood level of β-amyloid, Tau, and p-Tau in mild cognitive impairment and Alzheimer disease: A follow up study}},
  journal = {The Indian Journal of Medical Research},
  year    = {2026},
  doi     = {10.25259/ijmr_2164_2025},
  pmid    = {41949144},
  url     = {https://doi.org/10.25259/ijmr_2164_2025}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Mild cognitive impairment

Also tagged “biomarkers”

821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →